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Abstract
It has previously been shown that effective probiotics can accelerate gut maturation and
the development of a normal microflora in poultry. This results in increased resistance to enteric
pathogens encountered by chicks early in life. Our objective in experiments 1 and 2 was to
evaluate the effect of in ovo administration of FloraMax®-B11 (FM) on Marek’s disease (MD)
herpesvirus of turkeys (HVT) vaccine protective efficacy. In Exp. 1, day 18 White Leghorn
embryos were randomly distributed in four groups, 1) HVT vaccinated, no MDV challenge, 2)
HVT + FM vaccinated, no MDV challenge, 3) HVT vaccinated, challenge with virulent MDV,
4) HVT+ FM vaccinated, challenge with virulent MDV. Exp. 2 was designed the same as Exp. 1,
except chicks were challenged with a very virulent MDV strain. There was no significant
difference (P> 0.05) in MD incidence between birds vaccinated with and without FM in the HVT
vaccine. In Exp. 3 and 4, day 18 commercial broiler embryos were in ovo injected with either
saline or FM to measure hatchability, microbiota composition, morphometric analysis, and
Salmonella enterica serovar Enteritidis (SE) infection in chickens. The administration of the
probiotic did not negatively affect hatchability, but significantly reduced (P<0.05) coliforms
within the gut. In Exp. 4, the FM treated group showed significantly increased (P<0.05) BW at 7
days when compared to the controls. This is associated with the higher villi surface area
observed in the FM group and reduced (P<0.001) SE incidence and (P<0.05) CFU recovery. The
results of these studies suggest that the in ovo administration of FM into the amnion at 18 days of
embryogenesis does not impact the protection of the HVT vaccine against MD or negatively
affect hatchability. It also reduces the recovery of gram negative bacteria, improves BW during
the first 7 days, and decreases SE recovery in broiler chickens.
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Chapter I. Introduction
Until recently, antibiotics have long been used in the poultry industry. They have been
used to stimulate growth rate and feed efficiency and to control pathogenic bacteria. The
growing concern of antibiotic resistant bacterial strains and residues in food have caused
regulatory agencies and producers to reduce and even abandon the use of antibiotics. This
pressure has stimulated a need for viable alternatives to the antibiotics. A very promising
alternative is the use of probiotics. Due to this, there has been a recent surge in probiotic
development with encouraging results. However, in a commercial setting, chicks will not be able
to receive the beneficial bacteria until being placed in the chicken houses, where they can receive
it in the water or feed. Prior to this, chicks are exposed to the contaminated air within the hatch
cabinets and usually long, stressful transportation to their destinations. This allows pathogenic
bacteria to colonize and delay gut maturation and health within the newly hatched chick. In
poultry, there is a way to administer the probiotic before the chicks hatch. At Day 18 of
embryogenesis, almost all broilers are vaccinated for Marek’s Disease virus (MDV). This thesis
addresses the testing of a commercial probiotic and its ability to be administered with the
Marek’s vaccine, its effect on hatchability, and gut development and composition.
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Chapter II. Literature Review
Transfer of Microflora
The gut microbiota plays an important role in health by providing a barrier for
colonization of pathogens, by utilizing important metabolic functions (fermentation of
nondigestible fibers, production of short-chain fatty acids, and vitamin supplementation), and by
stimulating the development of the immune system (Guarner and Malagelada, 2003). At birth,
animals receive a natural inoculation of microbes, which establish themselves in the intestines.
This colonization of beneficial microflora allows the animal to resist potential environmental
challenges. In mammals, the inoculation occurs during parturition, with bacteria living in the
vaginal mucus, and through breast feeding (De Oliveira et al., 2014). Neonate gastrointestinal
tracts are sterile at birth, but the microorganisms near the vagina or anus of the mother rapidly
colonize the neonate after birth (Phillips et al., 2004). Within a few hours, bacteria begins to
appear in the feces. It is suggested that the gastrointestinal tract is first colonized by facultative
aerobes due to the intestinal environment showing a positive reduction potential at birth. As
these microbes consume oxygen, the environment transfers to a negative reduction potential and
allows the growth of strict anaerobes (Bezirtzoglou, 1997).
As stated earlier, during the first days of life, the bacteria colonizing the infant
gastrointestinal tract come primarily from the mother and the environment. For this reason, one
of the biggest determinants of the pioneer colonizers is the mode of delivery (Penders et al.,
2006). Infants born vaginally, are first colonized by the fecal and vaginal bacteria of the mother,
whereas cesarean section born infants are first exposed to bacteria in the hospital environment
and health care workers (Bezirtzoglou, 1997; Gronlund et al., 1999). Studies have shown vaginal
delivery at home resulted in higher colonization rates and counts of Bifidobacteria and

2

Bacteroides fragilis-group species and reduced incidence and counts of Clostridium difficile and
Escherichia coli when compared with cesarean section (Penders et al., 2006). The timing of
colonization and difference of bacterial populations between the two delivery methods can
persist for months or even the whole life of the individuals (Schultz et al., 2004; Rao et al.,
2009). Unfortunately, cesarean born infants are also usually more susceptible to intestinal
disorders (Gronlund et al., 1999; Penders et al., 2006; Cochetiere et al., 2007).
In birds, colonization occurs in nests through contact with brooding hens and nesting
materials (Mills et al., 1999). In modern poultry production, there is no contact between chicks
and hens, and chicks are first exposed to bacteria in the hatchery and chicken house environment.
Artificial incubation of poultry eggs has been shown to delay the colonization of beneficial
microflora due to the lack of interaction with adult birds (Hashemzadeh et al., 2010).
Gastrointestinal Tract
The GIT serves as the interface between the diet and the metabolic events that sustain
life. It is also the largest immune organ in the body, and serves as a barrier for prevention of
infection (Abreu-Martin and Targan, 1996; Mayer, 2000). The avian mucosal immune system
contains M cells, plasma cells, T cells, macrophages, intraepithelial lymphocytes, and heterophils
(Erickson and Hubbard, 2000). In poultry, a crucial factor in digestion and absorption of
nutrients are the intestinal villi, which are underdeveloped at hatch (Uni et al., 1995) and not
fully developed until 10 days of age (Noy and Sklan, 1997). As birds hatch, they must transition
from energy supplied via endogenous nutrients of the yolk to exogenous carbohydrate rich feed.
During this transition, significant changes occur both in morphology and intestinal size (Uni et
al., 1995). This maturation of the gut also affects the epithelial cell membranes, which are a
major mechanical barrier between the internal environment of the host and the external foreign
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material in the lumen (Rozze et al., 1982). By dietary means, it is possible to affect the
development of the gut and the competitiveness of both beneficial and harmful bacteria, which
can alter not only gut dynamics, but also many physiological processes due to the end products
metabolized by symbiotic gut microflora. Within the mucous layer, tight junctions between
epithelial cells and gut-associated lymphoid tissue help to maintain a homeostasis between
dietary antigens, in addition to enteric pathogens and beneficial microorganisms (Vicuna et al.,
2015). Dysbiosis within the gut, opens tight junctions which reduces barrier function, resulting in
nonselective permeability. This could lead to malabsorption of nutrients and translocation of
possible pathogenic enteric bacteria to various internal organs, which could result in disease and
reduced growth performance (Quinteiro-Filho et al., 2012). Recent poultry research has shown
that leakage of enteric bacteria into circulation results in non-gastrointestinal diseases (Tellez et
al., 2009; Borst et al., 2012; Wideman, 2013).
Microflora of the Gastrointestinal Tract
Naturally, animals are colonized by microorganisms that form a specific ecological
community of commensal, symbiotic, and pathogenic microorganisms or microbiota. Within this
microbiota, there are both permanently colonizing species and temporary colonizing species that
are characterized by a number of environmental microorganisms (Fiebiger et al., 2016). Warm
blooded vertebrates gastrointestinal (GI) tract constitutes one of the most densely populated and
diverse ecosystems known. The human GI tract’s microflora surpasses the number of cells in the
body ten-fold and the total mucosal surface area is up to 300 m2. This makes it the largest area of
the body interacting with the environment and it is colonized with over 1014 micro-organisms
(Lu et al., 2003; Bjorksten et al., 2006). For this reason, the gut microbiota are the most
important source of microbial stimulation and the driving force behind the postnatal maturation
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of the immune system (Bjorksten et al., 2006). Since the GI tract contains such a large number of
diverse microbes that can be commensal or pathogenic, they affect the host’s nutrient utilization
and intestinal development either positively or negatively (Dumonceaux et al., 2006).
A more complete understanding of the microbial ecology of the chicken intestinal
microbiome is necessary to reduce enteric disease and pathogens of public health concern.
Studies have shown that bacterial diversity and numbers vary throughout different sections of the
GI tract (Yegani and Korver, 2008). According to Donoghue et al (2007), it is estimated that
more than 500 bacterial species inhabit the poultry GI tract, however it is believed only 20% to
60% have been recovered by traditional culture methods (Lu et al., 2003). In the cecum, the most
abundant 16s rDNA sequences were homologous to Clostridiaceae at 65.6%, according to Lu et
al (2003). Conversely, Streptococci (Barnes et al., 1972) and Eubacterium (Salanitro et al., 1974)
have also been described as the most abundant sequences of bacteria in the cecum of broiler
chickens. In more recent studies, Ruminococcus, Lactobacillus, and Bacteroides were the most
predominant genera in the global sequence data set and in two 454 pyrosequencing studies (Qu
et al., 2008; Stanley et al., 2012a). However, Callaway et al. (2009) found Bacteroides and
Prevotella to be the most predominant genera in the chicken cecum and Nordentoft et al. (2011)
found Butyricimonas and Fecalibacterium were predominant. It is believed that differences in
host, feed, and analysis techniques might all contribute to the differences observed (Wei et al.,
2013).
There are few studies on the microbiome of populations within the small intestine of the
chicken gastrointestinal tract, as most have focused on the cecum. When Lu et al (2003)
sequenced microbiota of the small intestine, they found that the dominant bacteria in the ileum
was Lactobacillus. As chickens mature, microbial populations do change slightly, but of the 16s
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RNA sequences 70% belonged to Lactobacillus. It has also been shown that lactobacilli were the
main bacteria present in the duodenum and small intestine, and were also the only bacteria
present at a level above 104 CFU per gram by culture techniques (Barnes et al., 1972). Another
study that compared conventional or organic production conditions, also found that Lactobacillus
was the predominant bacteria present in the ileum of 42 day old broilers regardless of the
production setting (Bjerrum et al., 2006). Cressman et al. (2010) discovered that at day 7, fresh
litter chicks ileal mucosa was comprised of mainly Lactobacillus, followed by Lachnospiraceae
and Enterococcus. Whereas the ileal mucosa of chicks reared on reused-litter was primarily
colonized by bacteria within the order Clostridiales. Interestingly, in the reused litter,
Lactobacillus was more predominant in the ileum than in the fresh litter chicks. By day 42, the
fresh-litter birds had a microbiota similar to the reused-litter birds, which suggests diminishing
environmental effects, as intestinal bacteria from the excreta accumulates in the litter.
Concept of Competitive Exclusion
Metchnikoff (1908) first introduced the idea that intestinal microflora played a role in the
maintenance of health, when he studied lactic acid bacteria from fermented milk products. He
observed that Bulgarians who ate significant amounts of yogurt were more resistant to enteric
infections (Patterson and Burkholder, 2003). He hypothesized that the lactic acid bacteria in the
yogurt was providing this protection, and that the beneficial nature of these bacteria led to
prolonged life. The term Competitive Exclusion (CE) was first used by Greenberg (1969), where
he observed a species of bacteria outcompete another species for receptor sites in the intestinal
tract, in an article on the exclusion of Salmonella typhimurium from maggots of blow flies. He
discovered that without the reduction or elimination of normal intestinal microflora the S.
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typhimurium would not survive. Later, in 1971, van der Waaij and investigators while studying
pathogen colonization in mice, coined a synonymous term “colonization resistance”.
Competitive Exclusion
Competitive Exclusion has proven to be the best alternative route to control disturbances
within the intestines in poultry. Research worldwide was stimulated by an article in Nature in
1973 by Nurmi and Rantala, where they tried to control a Salmonella Infantis outbreak in broiler
flocks (reviewed by Schneitz, 2005). They revealed chicks were most susceptible to Salmonella
infections during the 1st week of life. They suggested this was due to the delayed establishment
of normal gut microflora in chicks raised in modern industry production methods. When a
Lactobacillus strain offered no protection, they decided to assess the effectiveness of CE, a
population of intestinal bacteria from adult chickens that were resistant to the S. infantis. They
administered the mixed culture orally and were able to achieve adult type resistance to
Salmonella (reviewed by Edens et al., 1997). Rantala and Nurmi (1973) recognized that
inoculating young chickens with unidentified GI tract contents could possibly cause a pathogen
to be introduced. So, cecal contents from healthy adult chickens were grown anaerobically and
passed three times prior to inoculating the chicks. The passages were intended to allow time to
check for specific pathogens and also to minimize the risk of pathogens in the culture. In their
experiment, day old chicks were treated with the passaged cecal content, diluted rumen content,
diluted fresh horse feces, or diluted crop and cecal contents of healthy adult chickens. The chicks
were then challenged 24 h post treatment with 103 Salmonella Infantis. All chicks receiving
chicken microflora tested negative for Salmonella, while all chicks receiving different species
bacteria were positive for Salmonella. From this study, it was demonstrated that the passaged
culture was as efficacious as the unpassaged and that there is host specificity because only the
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chicken cecal microflora were able to protect the chickens, unlike the horse or cattle feces
(Rantala and Nurmi, 1973).
Mechanism of CE
There are four major proposed mechanisms of CE: 1) creation of microecology that is
hostile to other bacterial species, 2) elimination of available bacterial receptor sites, 3)
production and secretion of antimicrobial metabolites, and 4) selective and competitive depletion
of essential nutrients (Rolfe, 1991).
The determining factor in the viability of microorganisms is the microecology of the
intestinal tract. Meynell (1963) determined that the production of volatile fatty acids at a pH
below 6.0 will decrease populations of Salmonella and Enterobacteriacea. The mechanism of
CE can be eliminated by use of antibiotics causing disruptions within the normal intestinal
microbial populations. This causes concentrations of volatile fatty acids produced by intestinal
bacteria to decrease, allowing for gut pH to increase to a more alkaline state (Edens et al., 1997).
It has been shown, in newly hatched chicks that the volatile fatty acid concentration and pH are
not adequate enough to chemically exclude pathogens (Barnes et al., 1979, 1980a,b).
In order for the host to be at risk to pathogens attaching to the intestinal epithelium, it is
required for there to be accessible sites for adhesion. According to Soerjadi et al. (1982), this
attachment is facilitated through the polysaccharide-containing components attached to the cell
wall. This component blocks all receptor sites by binding bacteria to each other and the
epithelium.
The antimicrobial substances produced and secreted by the endogenous bacteria of the
intestinal tract can either kill or inhibit growth of pathogens (Rolfe, 1991). Research has shown
that Lactobacillus as a group, produced significant amounts of bacterial growth inhibitory
8

substances (Edens et al., 1997). Talarico et al. (1988), revealed that the secretion of reuterin, by
L. reuteri had broad-spectrum killing capabilities within the intestinal tract of chickens.
The fourth mechanism, competition for available nutrients as a means to control intestinal
bacteria, is probably not the most effective means for CE. There are many environmental factors
that enhanced the availability of nutrients from the diet of the host or through manipulation of
dietary ingredients, favored the growth of certain populations (Rolfe, 1991). This could result in
the exclusion of other bacterial species. Casas et al. (1993) showed that influencing the lactose
concentration in the diet of chicks and poults, we can selectively provide an advantage for the
enhancement of L. reuteri.
Probiotics
The use of selected beneficial lactic acid bacteria as probiotics has been suggested for
many years due to their ability to prevent various enteric diseases and improve overall health
(Tellez et al., 2006). In 2006, the European Union banned the use of antibiotics as feed
supplements and recent concern in the United States has resulted in consumer’s requesting
antibiotic free chicken. This pressure has generated the need to find alternative options to the use
of antibiotics in the feed. A very promising alternative is the use of probiotics (Higgins et al.,
2005; Wolfenden et al., 2010; Barbosa et al., 2005).
The definition of probiotics according to the FAO/WHO (2001), is “live
microorganisms which, when administered in adequate amounts, confer a health benefit on the
host.” Probiotics have been used to treat intestinal disorders and improve intestinal health (Aureli
et al., 2010; Nicholson, 2002). In poultry, probiotics are used to supplement beneficial
colonization of the intestines in chicks after hatch (Fuller, 2001). They are also used to increase
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broiler performance (Lutful Kabir, 2009) and control the incidence of pathogens (La Ragione &
Woodward, 2003).
Patterson & Burkholder (2003) described ideal probiotics as, non-pathogenic, of host
origin, resistant to gastric and bile acids, ability to persist in the gastrointestinal tract, produce
antimicrobial substances, adhere to epithelium, modulate immune response, and tolerate
processing and storage. The most common types of probiotic bacteria are lactic acid bacteria,
such as Bifidobacterium spp., Lactobacillus spp., and Enterococcus spp. (Ljungh & Wadstrom,
2006). Lactic acid bacteria are Gram-positive bacteria that ferment carbohydrates into lactic acid
and energy. These bacteria are normally found within the gastrointestinal tract of humans and
animals. The most common LAB used as a probiotic is the genus Lactobacillus, a Gram-positive,
catalase negative, nonspore-forming, and facultative anaerobe. According to Hori (2010), there
are currently more than 125 identified Lactobacillus species.
Immunomodulation
Normal microflora of the GI tract is crucial for priming the immune system (GaboriauRouthiau, 2001), possibly due to beneficial, probiotic-type bacteria that are believed to modulate
the immune response (Christensen et al., 2003). Animals lacking normal microflora experience a
diminished degree of response to immune stimulus. It has been shown that germ-free animals
produce as little as one third of the normal antibody-producing B cells as conventional animals
(Mitsuoka, 1978). Intestinal bacteria are essential for the development of gut-associated
lymphoid tissue (GALT), which is important in the immune functions of the epithelium and the
development of the normal antibody repertoire. Commensal bacteria can be killed by enteric
macrophages, but survive within underlying dendritic cells of the gastrointestinal tract
(Macpherson and Uhr, 2004). These bacteria are presented to B cells in the mesenteric lymph

10

nodes which allows for an immune response of IgA. These dendritic cells also respond
differently to the normal commensal bacteria as opposed to potentially pathogenic ones. They
secrete different cytokines or are unresponsive, likely due to the expression of different toll-like
receptors on the differentiated dendritic cells (Christensen et al., 2003; Karlsson et al., 2004).
Stimulation of the innate immune system allows for improved acquired immune
responses through better antigen presentation (Chin and Mullbacher, 2003). Clinical studies have
reported a negative correlation between infectious disease and the presence of lactobacilli
(Alvarez-Olmos et al., 2004) and probiotic bacteria have been shown to increase the humoral and
cellular immune response against E. Coli (Miettinen et al., 1998) and Salmonella enterica
serovar Enteritidis (Koenen et al., 2004). It is possible that effects Lactobacillus have on the
immune system is contributed to secreted signaling molecules and not necessarily the presence
of the bacteria, as Lee et al (2004) showed an increase in T, NK, and MHC-II cells after several
administrations of cytoplasmic lactobacilli extracts.
It has been shown that inflammatory responses in the GIT are reduced by some
commensal, non-pathogenic bacteria (Drakes et al., 2004). This is explained by probiotic bacteria
inducing the expression of anti-inflammatory cytokines such as IL-10 and reducing the
expression of pro-inflammatory IL-1 (Lammers et al., 2003). With the increased expression of
cytokines that do not induce inflammation and the increased expression of MHC-II, it is possible
for the immune response to have a higher secretion of antibodies (Abbas et al., 2000).
Studies have shown that probiotics significantly increased antibody production in broilers
(Kabir et al., 2004) and that antibody titer in probiotic treated birds was significantly higher post
immunization of SRBC when compared to the controls (Khaksefidi and Ghoorchi, 2006). It has
also been demonstrated, that administration of probiotics enhances serum and intestinal natural
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antibodies to several foreign antigens in chickens (Haghighi et al., 2005). Dalloul et al. (2005)
studied the effects of the intestinal immune response to an Eimeria Acervulina infection when
Lactobacillus-based probiotics were supplemented in the feed. It was reported that the probiotic
afforded some measure of protection through immune modulation. The early immune response
was stimulated by the probiotic, characterized by early IFN-γ and IL-2 secretions which
improved local immune defenses against coccidiosis.

FloraMax
The commercial probiotic FM-B11 (FloraMax®) is a defined 11-isolate LAB culture of
the genus, or related to, Lactobacillus. This product was used in a field trial with 234,105
broilers in Mexico (Vicente et al., 2007). The birds treated with FM-B11 showed a 2.06%
improvement in bodyweight, a 3.5% improvement in feed conversion, and a .9% reduction in
mortality when compared to the controls. The same probiotic was used in a commercial turkey
field trial where they reported increases in average daily gain and body weight of 1.63g and 190g
respectively over untreated controls. The costs of production were also compared between the
treated and untreated groups and the cost per kilogram of meat was reduced by $0.0153 in the
probiotic treated group (Torres-Rodriguez et al., 2007).
A study was performed to evaluate the efficacy of typical prophylactic antibiotic use
compared with the use of probiotics, or a combination of both in turkey brooding houses deemed
likely to experience an outbreak of idiopathic diarrhea (Higgins et al., 2005). In the experiment,
the poults receiving FM-B11 periodically in the drinking water had significantly higher mean
body weights than the control group and numerically higher weights than the other probiotic
group and antibiotic groups. In another experiment, the poults were experiencing a severe
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Salmonella Senftenberg infection and were administered FM-B11 or antibiotics plus another
probiotic. Between d 12 and 47 the poults receiving the antibiotic and other probiotic gained
significantly more weight than FM-B11 alone or the untreated controls. However, weight gain at
the end of the experiment between d 29 and 47 no differences in BWG across all treatments were
reported. (Higgins et al., 2005).
Higgins et al. (2007) evaluated the ability of FM-B11 to reduce the amount of
recoverable Salmonella from the ceca of broiler chicks. In their first 3 experiments, the
administration of the probiotic 1 hour post Salmonella enterica serovar Enteritidis or Salmonella
Typhimurium challenge significantly reduced the incidence of Salmonella recovery, 60-70% and
89-95% respectively, from the cecal tonsils when compared to the control group, 24 hours post
treatment. They also observed a 2.9 log10 reduction in Salmonella enterica serovar Enteritidis
recovery from probiotic treated birds when compared to the controls, 24 hours post treatment. In
the next 4 experiments, FM-B11 again significantly reduced cfu recovery 24 hours post
treatment, the probiotic also reduced cfu recovery at 12 hours post treatment, even though there
was no difference in incidence. FM-B11 was also shown to reduce Salmonella enterica serovar
Enteritidis. The encouraging data collected from FM-B11 administration resulted in a
commercial product that is currently used in the poultry industry.
Marek’s Disease
Marek’s disease (MD) is one of the most widespread avian diseases and can be found in
chicken flocks worldwide. The disease was first recognized by Jozsef Marek, a Hungarian
veterinarian in 1907 (Sluis, 1997). It is a highly contagious disease caused by a herpes virus and
is identified by the presence of lymphoid tumors in various organs (Okazaki et al., 1970). This
airborne pathogen costs the poultry industry $1-2 billion annually (Morrow and Fehler, 2004), by
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causing paralysis, condemnations and high mortality due to T cell lymphomas and peripheral
nerve damage (Reddy et al., 1996). The disease may survive for months or years in the litter or
poultry dust. Since the virus is inhaled, infection occurs through the respiratory tract and infected
birds continue to be carriers long after their infection. Chickens are usually infected at an early
age, however lesions are normally not seen until 8-24 weeks of age. At first, all attempts of
isolation, sanitation, and genetic resistance to protect flocks from the disease were mostly
unsuccessful.
Over the past 40 years, the poultry industry has depended on a series of avirulent or
attenuated live virus vaccines to provide protection against field strains of Marek’s disease in
chickens (Calnek, 2001). These vaccines are the first effective practical means for the control of
any neoplastic disease in man or animals. Marek’s disease virus-1 (MDV1) causes the condition
known as MD in chickens (Churchill and Biggs, 1967). Herpes virus of turkeys (HVT/MDV3)
and MDV2 are naturally occurring, infectious viruses that are apathagenic and non-oncogenic in
chickens, and are used as vaccines against MD either separately or in combination (Witter et al.,
1970). Viruses from all three serotypes have been used as cell-associated live vaccines. In the
1970s, the HVT vaccine provided tremendous protection for a short period of time, until there
was a decline in the efficacy of monovalent HVT vaccine due to interference from homologous
maternal antibodies and to the development of MDV field strains of increased virulence. By the
1980s, a bivalent vaccine composed of a mixture of HVT and the serotype 2 strain SB-1 was
introduced. This vaccine offered better protection than either of the individual components used
alone, a well-known phenomenon protective synergism (Witter and Lee, 1984). As field viruses
continued to increase in virulence, the attenuated serotype 1 strain CVI988 known as Rispens
vaccine was implemented for extensive use in the 1990s (Rispens et al., 1972). The CVI988 is
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still the most widely used vaccine and is the most protective due to being a serotype 1 and the
most closely antigenically related to field strains (Baignet, 2006).
The vaccines establish a persistent infection which helps to reduce early viremia, after
exposure to pathogenic strains. It also protects against tumor formation and mortality which
takes away economic consequences due to infection (Morimura et al., 1998). MDV vaccines
however, do not prevent super-infection due to challenge viruses. The challenge virus still
multiplies and sheds from feather tissues and is oncogenic to non-vaccinated birds. The selection
pressure forced on these virulent viruses in vaccinated birds is instigating evolution of field
viruses towards pathotypes of greater virulence (Witter, 1997). Even though current vaccines are
effective, an ideal vaccine would prevent replication of the virus or shedding.
Inoculation of the vaccine into day-old chicks is followed by replication of the virus a
few days later in the lymphoid organs. Then, the vaccine infected lymphocytes are released into
the peripheral blood. For optimal protection, the vaccine needs 1-2 weeks between vaccination
and exposure. This allows the vaccine virus to enter into the latency stage of infection. It is
believed that there is a two-step mechanism of protection. First, the antigens of the vaccine virus
are similar to those of the virulent strains and these antigens stimulate an immune response to the
virulent virus. This results in decreased viremia, viral replication, malignant transformation, and
immunosuppression (Baignet et al., 2006). The second step is MDV tumor antigens stimulating
the immunological rejection of tumor cells by cytotoxic T cells (Powell, 1978).
Vaccines used to be administered to day-old chicks subcutaneously in the neck or
intramuscularly in the leg using a semi-automated device. This machine relies on the operator to
correctly press the chicken against the needle to receive the full dose and could only vaccinate up
to 3,000 birds per hour. Due to this laborious task that cost a lot of time and money, now
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hatcheries use an in ovo delivery system to administer the vaccine to embryos at transfer from
the setters to the hatchers (day 18). These machines are equipped with individual floating
injectors that can adjust automatically for uniform needle depth in eggs of all sizes and
administer a precise dose to 30,000 eggs per hour. The machine also sanitizes the needles after
each injection and accurately distinguishes live from infertile or dead embryos and delivers
vaccine only to viable eggs. With this method, 100% of chicks are correctly vaccinated against
MDV and the timely administration allows for early and effective stimulation of the immune
response (Baignet et al., 2006) In 2006, Baignet et al. (2006) reported that a total of 4.2 billion
layers, 0.5 billion breeders, and 17 billion broilers are vaccinated annually worldwide.
In Ovo Technology
The agriculture industry is reducing and eliminating drug use as growth promoters in
animal diets. These antibiotic growth promoters were used to control poor intestinal conditions
caused by dysbacteriosis or parasites, by adding lows doses of the AGP and coccidiostats to
commercial poultry diets (De Oliveira et al., 2014). Therefore, many alternatives to growth
promoters are now available (Buchanan et al., 2008; Kim et al., 2011). Preferably, usage of drugs
in production would be avoided by prevention of diseases rather than treatment. This could be
achieved by prophylactic administration of probiotics that prevent colonization of pathogens
(Cukrowska et al., 2002). In poultry, colonization is thought to take place after hatching,
however there is some evidence from Pedroso (2009) and Bohorquez (2010) that before hatch,
small numbers of live bacteria can be found in the intestines. Even though probiotics (DFM) are
often used in the pre-starter and starter diets, chicks can be exposed to pathogenic bacteria within
the hatchery long before they ever consume any feed (De Oliveira et al., 2014).
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Fertile eggs from breeder farms can be contaminated with many bacteria that are on the
shells surface or that have penetrated beneath the shell. This can be from contaminated nesting
material or the simple fact that a freshly laid, warm, wet egg is highly susceptible to
contamination from microorganisms (Cox et al., 1991). At hatch, chicks have an unestablished
microflora in their gut and are highly susceptible to intestinal colonization of enteric pathogens
within the hatching environment (Cox et al., 1992). Bacteria such as Salmonella and E. coli can
also penetrate the eggshell and proliferate as incubation conditions similarly favor these
microorganisms. These bacteria do not usually affect the chick from hatching and consequently
create widespread bacterial reservoirs within commercial hatcheries (Cox et al., 1990).
Therefore, the presence and persistence of bacterial contamination within the hatchery implies
that the susceptible day-of-hatch chicks could be at a greater risk of colonization by pathogenic
bacteria in the hatchery than during grow-out (Cox et al., 1990). With this knowledge that the
first microbes the chicks may come into contact with could be pathogenic, it seems intuitive that
we should not leave pioneer intestinal colonization to chance when we can intentionally
inoculate with beneficial bacteria (Cukrowska et al., 2002).
The concept of in ovo CE was first put forth in the 1990s when chicken embryos were
inoculated into the air cell membrane (Cox et al. 1992). However, previous attempts of this
method resulted in practical issues such as higher post hatch mortality and reduced hatchability
(Cox et al., 1992; Meijerhof and Hulet, 1997). Cox et al. (1992) administered a CE culture from
1 year old, Salmonella-free caged layers that was grown anaerobically and passed once. Embryos
were injected onto the air cell membrane or below the air cell membrane. Only the 1:1,000 and
1:1,000,000 dilutions administered into the air cell resulted in higher hatchability numbers that
still were not acceptable, 81% and 78% respectively compared to the controls at 96%. The
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1:1,000 dilution group also acquired resistance to an oral challenge of S. typhimurium (106) at
day of hatch when compared to the controls. A subsequent experiment demonstrated that dose
and delivery depth had an effect on chick hatchability (air cell and amnionic fluid).Doses ranging
from undiluted to 1:1,000,000 of CE culture had a significant negative effect on hatchability. Air
cell administration reduced hatchability, but chicks showed Salmonella resistance at hatch.
However, when the CE mixture was administered into the amnionic fluid, the undiluted and
1:1,000 dilution prevented any hatching, and the 1:1,000,000 dilution hatched less than 50%.
Edens et al. (1997) were able to successfully apply in ovo Lactobacillus reuterin in the air
cell and amnion without having negative effects on hatchability. All studies reported since Edens
(1997) paper have concentrated on in ovo inoculation of different bacteria into the air cell due to
the work of Cox et al. (1992), however those studies have all had a negative impact on
hatchability (Meijerhof and Hulet, 1997; Hashemzadeh et al., 2010; Hosseini-Mansoub et al.,
2011; Yamawaki et al., 2013). The reasons these studies saw differences could be due to factors
such as delivery technique, site of injection (air cell vs. amnion), type of bacteria used, and
inoculated dose (De Oliveira et al., 2014). These are all vital parameters that must be considered
in order to successfully inoculate bacteria in ovo. This was demonstrated by De Oliveira et al.
(2014), where 14 different bacterial isolates were in ovo injected and it was found that some
strains were lethal regardless of dose and some lethal due to dose. This confirmed results of
Edens et al. (1997), that there is no reason to avoid amnion inoculation based on hatchability if
strains are tested for negative effects and adjusted to avoid this issue. Amnion injections are a
preferred method because it eliminates the complications of other techniques such as, imprecise
dose reaching the chick by air cell and spraying delivery and practical issues of individual bird
inoculation of oral gavage and vent lip application (De Oliveira et al., 2014). Due to current in
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ovo technology, the administration of vaccines, probiotics, and other components should be
combined into a single dose, given together for individual and precise delivery.
In ovo vaccination is currently the standard procedure for the application of Marek’s
disease virus and infectious bursal disease vaccines in the hatchery for broiler chickens in the
United States (Williams and Zedek, 2010). Newly hatched chicks encounter many antigens
during the first few days of life, while their immune system is still developing. The highest
mortality in commercial chickens usually occurs within the first 7 days of life.
Summary
Due to the intense pressure on the poultry industry and the scientific community to find
alternatives to antibiotics for food producing animals, the industry is in need of a replacement
therapy for fighting enteric disease in poultry. In commercial poultry, the chicks do not receive
beneficial microflora from the hen. Instead, the first exposure they have is the contaminated air
inside the hatch cabinets. This allows for pathogens such as Salmonella or E. coli to have an
opportunity to be the pioneer colonizers of the developing embryo’s gut. With the surge in
probiotic development and the promising results that have been observed, if a proper candidate
probiotic could be administered before hatching, the embryo could be colonized with beneficial
bacteria before leaving the egg. In poultry, this is possible due to in ovo technology and the
administration of the Marek’s disease vaccine at day 18 of embryogenesis. This is a promising
method with commercial application if the right probiotic could be mixed with the vaccine and
administered together in one package.
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ABSTRACT
Four experiments were conducted to evaluate the effect of in ovo administration of FloraMax®B11 (FM) on Marek´s disease (MD) herpesvirus of turkeys (HVT) vaccine protective efficacy,
hatchability, microbiota composition, morphometric analysis and Salmonella enteritidis (SE)
infection in chickens. In Exp. 1, day 18 White Leghorn embryos were randomly distributed in four
groups: 1) HVT vaccinated in ovo and no Marek’s disease virus (MDV) challenge; 2), HVT + FM
vaccinated in ovo and no MDV challenge; 3) HVT vaccinated in ovo and challenge with virulent
MDV (vMDV; strain 583A); 4), HVT + FM vaccinated in ovo and challenge with vMDV. Exp. 2
was designed exactly the same as Exp. 1 but chicks were challenged with very virulent MDV
(vvMDV; strains Md5 and 612). In both experiments, birds were monitored until 8 wk of age, and
tested for MD incidence. Exp. 3 and 4, day 18 commercial broiler embryos were injected in ovo
with either saline or FM to measure hatchability and gastrointestinal composition. In addition, in
Exp. 4, all chickens that hatched were then orally gavaged with SE at hatch and kept for 7 d to
monitor post hatch BW. In Exp. 1 and 2, there was no significant difference (P > 0.05) between
% MD in birds vaccinated with HVT alone or HVT + FM. In Exp. 3 and 4, administration of the
probiotic did not negatively affect hatchability, but did reduce coliforms. Further, increase in BW
was associated with higher villi surface area in ileum in chickens that received the probiotic as
well as a significant reduction in the SE incidence. These results study suggest that in ovo
administration of FM does not negatively impact the ability of HVT to protect against MD or
hatchability of chickens, and improves BW during the first 7 d of life and decreases SE recovery
in broiler chickens.

Key words: In ovo, Marek’s disease vaccine, probiotic, chickens, hatchability
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INTRODUCTION
Bacterial communities living and colonizing in the gastrointestinal tract of animals outnumber total
somatic cells of metazoans by an estimated 10-fold (Neish, 2009). Today, the microbiome is
recognized as the ‘forgotten organ,’ operating like an organ within the host and orchestrating
numerous physiological and biological functions that have a profound impact on the balance
between health and disease (O’Hara and Shanahan, 2006; Tellez, 2014). Early establishment of
the microbiome have been reported to improve the assembly of the gut-associated lymphoid tissue
(Martin et al., 2010), intervene in the development of the immune system (McFall-Ngai, 2007),
maintain mucosal barrier integrity (Duerkop et al., 2009), modulate proliferation of enterocytes
(Moran, 2007), adjust blood flow (Sekirov et al., 2010), regulate the enteric nervous system
(Tlaskalová-Hogenová et al., 2011), and improve digestion of nutrients (Dass et al., 2007; Walter
et al., 2011; Qiu et al., 2012). Essential colonization of these bacterial populations starts at
birth/hatch, and is followed by progressive assembly of a complex and dynamic microbial society
(Di Mauro et al., 2013).
Under commercial conditions, millions of chickens and turkeys hatch in a hostile
environment, and are exposed for several hours to heat stress and potential pathogenic bacteria in
the hatcheries. Increased stress along with the potential abundance of pathogens in the hatching
cabinet leads to ideal conditions for pathogen colonization. It is generally accepted that the natural
route of transmission of zoonotic pathogens such as Salmonella, is fecal-oral (White et al., 1997;
Galanis et al., 2006). However, published studies have also suggested that airborne transmission
of Salmonella in poultry is possible (Wathes et al., 1988; Baskerville et al., 1992; Leach et al.,
1999; Fallschissel et al., 2009). Understanding the anatomical and immunological defenses of the
avian respiratory tract helps to clarify this issue. Architecture of the avian respiratory tract is an
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important component to susceptibility and resistance to infectious agents. In day old chickens and
turkeys, no or very few infiltrating lymphocytes are seen in the primary bronchi region (Fagerland
and Arp, 1990; Smialek et al., 2011) and it isn’t until 3-4 weeks of age the lymphoid nodules are
developed at these locations (Fagerland and Arp, 1993; Drolet et al., 2010). During the following
week, the number of IgG, IgA or IgM-producing cells continues to increase, however, the
bronchial-associated lymphoid tissue (BALT) is not mature until chickens are 6–8 weeks old
(Bienenstock, 1980; Bienenstock and McDermott, 2005; De Geus, 2012). Hence, commercial
neonate poultry are extremely susceptible to airborne pathogens, regardless of respiratory or
enteric bacteria (Arshad et al., 1998). In support of these findings, our laboratory has recently
showed that transmission by the fecal-respiratory route is a viable portal of entry for Salmonella
(Kallapura et al., 2014a,b,c). This mode of infection could explain some clinical expression of
relatively low-dose infectivity under field conditions in relation to the high oral challenge dose
that is typically required for infection through the oral route in laboratory studies. This also
supports previous studies demonstrating fan driven spread of Salmonella within the hatching
cabinet and hatchery incubators (Hashemzadeh et al., 2010).
Over a century ago, Eli Metchnikoff proposed the ground-breaking idea to ingest viable
bacteria to endorse health (Metchnikoff, 1908). This concept is more appealing today, since
antimicrobial resistant bacteria have become a problem in many countries (Kiser, 1976; Dahiya et
al., 2006; Teillant and Laxminarayan, 2015). The imminent ban of antibiotics in animal feed
creates a challenging scenario for expansion of alternative prophylactics (Parker, 1990; Dahiya et
al., 2006; You and Silbergeld, 2014). Probiotics and direct-fed microbials are becoming accepted
as one of the best tools on keeping gastrointestinal health and promoting performance in poultry
raised without antibiotics (Dominguez-Bello and Blaser, 2008). In addition to improving intestinal
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microbial balance, metabolism, and gut integrity (Isolauri et al., 2002; Salminen and Isolauri,
2006), studies have also shown that probiotics have anti-inflammatory (Borchers et al., 2009; Lyte,
2011), anti-oxidant (Farnell et al., 2006; Tao et al., 2006; Zareie et al., 2006; Segawa et al., 2011;
Howarth and Wang, 2013), and enhacing barrier integrity properties (Yu et al., 2012).
Furthermore, several researchers have confirmed benefits of probiotics on innate immunity
(Alvarez-Olmos and Oberhelman, 2001; Vanderpool et al., 2008; Molinaro et al., 2012) as well as
humoral immunity (Arvola et al., 1999; Haghighi et al., 2006; Howarth and Wang, 2013).
FloraMax®-B11 is a defined lactic acid bacteria (LAB) probiotic culture that has
demonstrated an accelerated development of normal microflora in chickens and turkeys. It
provides increased resistance to Salmonella spp. infections (Farnell et al., 2006; Higgins et al.,
2007, 2008, 2010; Vicente et al., 2007; Menconi et al., 2011, 2013; Tellez et al., 2012; Biloni et
al., 2013; Delgado et al., 2014), reduces idiopathic diarrhea in commercial turkey brooding houses
(Higgins et al., 2005), as well as increased performance and reduced costs in poultry (TorresRodriguez et al., 2007; Vicente et al., 2008). However, no studies have been evaluated for
administration of FloraMax®-B11 in ovo, and the only practical and reliable way to evaluate this
route of administration, would be mixing it with the diluent of the Marek’s disease (MD) vaccine.
Hence, the objective of the present study was to evaluate the effect of the in ovo administration of
FloraMax®-B11 on MD vaccine herpesvirus of turkeys (HVT) protective efficacy, hatchability,
microbiota composition, morphometric analysis, and SE infection in chickens.
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MATERIAL AND METHODS
Probiotic Culture
FloraMax®-B11 (Pacific Vet Group USA Inc., Fayetteville, AR) is a defined probiotic culture
derived from poultry gastrointestinal origin that contains proprietary strains of LAB.
In ovo evaluation of FloraMax®-B11 on Marek´s disease HVT vaccine
Chickens and Viruses. Maternal-antibody-negative, White Leghorn 15I5x71 chickens were used
in these experiments (Bacon et al., 2000). These MD-susceptible chickens were from an SPF
breeding flock with no MD vaccinations or exposure that tested negative for MDV antibodies,
exogenous avian leukosis virus, and reticuloendotheliosis virus by routine surveillance testing. All
birds were housed in negative-pressure Horsfall-Bauer isolators, and experiments were conducted
following approval by the USDA Avian Disease and Oncology Laboratory (ADOL) Animal Care
and Use Committee. Viruses were propagated on primary duck embryo fibroblasts (DEF)
maintained in Leibovitz L-15 medium plus McCoy 5A medium (1:1), supplemented with 2.5%
bovine serum and antibiotics (Witter et al., 1980). In experiment 1, chickens were challenged with
the MDV strain 583, a virulent (v) strain. In experiment 2, chickens were challenged with MDV
strains Md5 or 612, both very virulent (vv). HVT is a commercial vaccine, and was prepared and
utilized as recommended by the manufacturer.
Experimental Design
Experiment 1. Chicks were randomly distributed into four groups (each with 17 birds) in two
independent trials: 1) HVT vaccinated in ovo and no MDV challenge; 2) HVT + FloraMax®-B11
vaccinated in ovo and no MDV challenge; 3) HVT vaccinated in ovo and challenged with MDV;
4) HVT + FloraMax®-B11 vaccinated in ovo and challenged with MDV. MD vaccine was
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administered in ovo at the manufacturer recommended dosage either alone or with FloraMax®B11 (104 cfu). Birds were monitored until 8 wk of age, then humanely euthanized and evaluated
for MD incidence. Chickens were considered MD positive if peripheral nerve enlargements,
tumors, or both were present at necropsy. When enlarged nerves or gross tumors were in question,
tissue samples were collected and processed for microscopic evaluation. Chicks that died during
the first wk of placement were considered nonspecific chick mortalities and were excluded from
the experiment.
Experiment 2. The identical conditions were used as described for experiment 1 except that MDV
strains Md5 and 612 were used instead of strain 583A and the experiment included only one trial.
Effect of in Ovo Application of FloraMax®-B11 on Hatchability and Microbiota Composition..
Experiment 3 consisted of three independent trials. Eighteen-day-old embryos were obtained from
Cobb-Vantress (Siloam Springs, AR). In each trial, eggs were candled and inoculated with either
saline or 104 cfu of FloraMax®-B11 via in ovo injection into the amnion. The two treatment groups
were placed in separate hatchers to avoid cross contamination. On d 21, chicks were pulled from
hatchers and hatchability was determined. In each trial, 12 chickens from each group were
humanely euthanized to evaluate gastrointestinal composition on selective media as describe
below.
Enumeration of Bacteria. For trial 1, the whole gut (ventriculus to cecum) was aseptically
removed. For trials 2 and 3, the fore gut (ventriculus to Meckel’s diverticulum) and hind gut
(Meckel’s diverticulum to cecum) were removed separately. Sections were collected into sterile
bags and homogenized. Samples were weighed and 1:4 wt/vol dilutions were made with sterile
0.9% saline. Ten-fold dilutions of each sample, from each group were made in a sterile 96 well
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Bacti flat bottom plate and the diluted samples were plated on two different culture media; to
evaluate total number of LAB in Man Rogosa Sharpe (Difco™ Lactobacilli MRS Agar VWR cat.
no. 90004-084, Suwanee, GA 30024); total coliforms in MacConkey (VWR cat. no. 89429–342,
Suwanee, GA 30024).

Evaluation of in Ovo Administration of FloraMax®-B11 on Body Weight, Salmonella enteritidis
Recovery, and Morphometric Analysis in Broiler Chickens. In experiment 4, the challenge
organism used in all experiments was a poultry isolate of Salmonella enterica (SE) serovar,
Enteritidis, bacteriophage type 13A, obtained from the USDA National Veterinary Services
Laboratory, Ames, IA. This isolate was resistant to 25 µg/mL of novobiocin (NO, cat. no. N-1628,
Sigma, St. Louis, MO 63103) and was selected for resistance to 20 µg/mL of nalidixic acid (NA,
cat. no. N-4382, Sigma) in our laboratory. For the present studies, 100 µL of SE from a frozen
aliquot was added to 10 mL of tryptic soy broth (cat. no. 22092, Sigma) and incubated at 37°C for
8 h, and passed three times every 8 h to ensure that all bacteria were in log phase. Post-incubation,
bacterial cells were washed 3 times with sterile 0.9% saline by centrifugation at 1,800 × g for 10
minutes, reconstituted in saline, quantified by densitometry with a spectrophotometer (Spectronic
20D+, Spectronic Instruments Thermo Scientific, Waltham, MA 02451), and diluted to an
approximate concentration of 108 cfu/ml. Concentrations of SE were further verified by serial
dilution and plating on brilliant green agar (BGA, cat. no. 70134, Sigma) with NO and NA for
enumeration of actual cfu used to challenge the chickens.
In this trial, 300 eighteen-day-old embryos were received from Cobb-Vantress. At d 18,
eggs were candled and inoculated with either saline or 104 cfu FloraMax®-B11 via in ovo injection
into the amnion. The two treatment groups were placed in separate hatch cabinets placed in
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separate rooms to avoid cross contamination. On d 21, chicks were pulled from hatchers to measure
hatchability. All chickens were then orally gavaged with SE on d of hatch (~104 cfu/chick).
Twenty-four hours post inoculation (PI), twenty chickens were euthanized with carbon dioxide
asphyxiation to determine SE intestinal colonization as described below. From these chickens, 5
samples were also taken to determine intestinal morphometric analysis as described below. BW
was determined at d 1, 3, and 7. Chickens were provided ad libitum access to water and a balanced
unmedicated corn-soybean diet meeting the nutrition requirements of poultry recommended by
NRC (1994). All animal handling procedures were in compliance with Institutional Animal Care
and Use Committee at the University of Arkansas.
Salmonella Recovery
Ceca-cecal tonsils (CCT) were homogenized and diluted with saline (1:4 by wt/vol) and tenfold
dilutions were plated on BGA with NO and NA, incubated at 37°C for 24 h to enumerate total SE
colony forming units. Following plating to enumerate total SE, the CCT samples were enriched in
double strength tetrathionate enrichment broth and further incubated at 37°C for 24 h to enrich.
Following this, enrichment samples were plated on BGA with NO and NA and incubated at 37°C
for 24 h to confirm presence/absence of typical lactose-negative colonies of Salmonella.

Intestinal Morphological Analysis
For enteric morphometric analysis ileum and duodenum samples were collected (n = 5). A 1-cm
segment of the midpoint of the duodenum and the distal end of the lower ileum from each bird was
removed and fixed in 10% buffered formaldehyde for 48 h. Each of these intestinal segments was
embedded in paraffin, and a 5-μm section of each sample was placed on a glass slide and stained
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with hematoxylin and eosin for examination under a light microscope. All morphological
parameters were measured using the ImageJ software package (http://rsb.info.nih.gov/ij/). Ten
replicate measurements for each variable studied were taken from each sample, and the average
values were used in statistical analysis. Villus length (VL) was measured from the top of the villus
to the top of the lamina propria (Yitbarek et al., 2013). Crypt depth was measured from the base
upward to the region of transition between the crypt and villus (Biloni et al., 2013). Villus width
(VW) was measured at the widest area of each villus, whereas the villus:crypt ratio was determined
as the ratio of villus height (VH) to crypt depth. Villus surface area (VSA) was calculated using
the formula (2π)(VW/2)(VL), (Sakamoto et al., 2000).

Statistical Analysis
All data were subjected to one-way analysis of variance as a completely randomized design using
the GLM procedure of SAS (SAS Institute, 2002). Data is expressed as mean ± standard error.
Significant differences among the means were determined using Duncan’s multiple-range test at
P < 0.05. MDV as well as SE incidence data were expressed as positive/total chickens (%), and
the percent recovery of SE was compared using the chi-squared test of independence, testing all
possible combinations to determine the significance (P ≤ 0.001) for these studies (Zar, 1984).
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RESULTS
This study addressed three major concerns: 1) whether in ovo administration of FloraMax®-B11
mixed with MD vaccine would negatively impact vaccine efficacy, 2) the effect of in ovo
administration on hatchability and microbiota composition and 3) the impact on Salmonella
infections in broiler chickens. Experiment 1 consisted of two independent replicates to determine
if there was any difference when birds were vaccinated in ovo with HVT only or with HVT +
FloraMax®-B11 followed by challenge with vMDV. The results of the in ovo evaluation of
FloraMax®-B11 on HVT vaccine efficacy in experiments 1 and 2 are summarized in Table 1. In
both experiments, there was no significant difference between % MD in birds vaccinated with
HVT alone or HVT + FloraMax®-B11, although numerical differences between treatment suggest
that probiotics may have slightly improved protection immunity in birds challenged with MDV
strain 583. This benefit was not apparent when we used vvMDV strains (Md5 and 612) in
experiment 2 (Table 1).
The effect of in ovo administration of the probiotic FloraMax®-B11 on hatchability in
experiment 3 is displayed in Table 2. There was no significant difference in hatchability between
embryos administered probiotics or the controls. The results of the effect of in ovo application of
FloraMax-B11® on microbial composition in the gastrointestinal tract of hatching broiler chickens
in experiment 3 are summarized in Table 3. In trials 1 and 3, chickens treated with FloraMax ®B11 showed a significant reduction in coliforms recovery when compared with saline control
group at d of hatch. In trial 2, the treated group had numerically lower recovery than the control
group and in fact had reduced gram negatives to non-recoverable numbers. With the exception of
hindgut in trial 2, a significant increase in the total number of LAB was observed in probiotic
group when compared with saline treated group (Table 3).
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The results of in ovo administration of FloraMax®-B11 on hatchability, BW and SE
recovery in broiler chickens of Experiment 4 are summarized in Table 4. In this experiment, no
significant changes were observed in hatchability or the BW of the neonates when they were
removed from the hatching cabinets; however, a significant increase in BW was observed in
chickens that received the probiotic when compared with saline control groups on d 3 and 7 (Table
4). Interestingly, chickens that received the probiotic, showed a significant reduction in the
incidence and total SE cfu numbers recovered from CCT when compared with saline control
chickens (Table 4).
The results of the effect of in ovo application of FloraMax®-B11 on morphometric analysis
of the gastrointestinal tract of hatching broiler chickens of experiment 4 are summarized in Table
5. A numerical increase in VH, VW, and VSA was observed in the treated group when compared
to the controls for the duodenum. Nevertheless, embryos that received the probiotic showed a
significant increase in the villus:crypt depth ratio when compared with saline control group. In the
ileum, there was a significant increase in VH, VSA, and crypt depth in the probiotic treated group
when compared to the control group.
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DISCUSSION
MMD is a lymphoproliferative disease of domestic chickens caused by an oncogenic α-herpesvirus
(Churchill and Biggs, 1967; Calnek, 2001). The disease is associated with lymphomas, neurologic
manifestations, and immune suppression (Calnek, 2001). Without a question, MD has been a major
concern to the poultry industry for over half a century (Nair, 2005), and the modern poultry
industry as we know it today, would not exist without the development of MD vaccines (Baigent
et al., 2006; Gimeno, 2008; Parvizi et al., 2010; Silva et al., 2010; Dunn and Silva, 2012). The
virus is so abundant and stable in the environment, that vaccination at the hatchery is the only
effective method to control MD in commercial flocks (Witter et al., 1980, 2005; Baigent et al.,
2006; Dunn et al., 2010). Due to the significant economic and immunosuppression impact, modern
commercial chickens are vaccinated before they leave the hatchery.
Although, we have reported the benefits of spray application of FloraMax®-B11 in the
hatcheries (Wolfenden et al., 2007), this is the first report of in ovo application of this defined
probiotic, mixed with HVT vaccine simultaneously. One of the two major concerns we addressed
in this study was whether in ovo administration of FloraMax®-B11 mixed would negatively affect
MD vaccine protective efficacy. The results of experiments 1 and 2, demonstrated that there was
no negative impact and even possibly a small improvement of the probiotic depending on the MDV
challenge strain. As far as we are aware, this is the first report showing the possibility of combining
a probiotic with an in ovo MD vaccine showing no negative effect. The other major concern with
in ovo application of FM was on broiler hatchability, but in every trial conducted the probiotic also
showed no negative effects on hatchability.
In the present study, it was remarkable to observe that embryos, which received the
probiotic before hatch, had a significant reduction in coliforms when compared with saline treated
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chickens (Table 3). Although there is extensive evidence demonstrating that this particular
probiotic is able to control Salmonellae infections in poultry in both, laboratory or commercial
conditions (Farnell et al., 2006; Higgins et al., 2007, 2008, 2010; Vicente et al., 2007; Menconi et
al., 2011, 2013; Tellez et al., 2012; Biloni et al., 2013; Delgado et al., 2014). This current study
further validated the probiotics efficacy via in ovo administration by reducing the recovery of SE
when chickens were challenged at d of hatch and cultured 24 h later (Table 4). These results are in
agreement with the work of De Oliveira et al. (2014) who demonstrated that in ovo colonization
with probiotic could become an important method to reduce Salmonella and other intestinal
bacterial infections in poultry.
In experiment 4, the significant increase in BW in treated chickens at d 3 and 7 (Table 4),
were associated with significant morphometric changes in the duodenum and ileum observed at d
1 (Table 5). It is likely that the higher BW in the probiotic treated group was due to the increase
VH, leading to more VSA leading to better nutrient absorption. These results are quite impressive,
when a newly hatched modern d broiler chick increases its BW by 25% overnight and 5000% by
5 wk, to 2kg (Choct, 2009). Similarly, it is also important to consider the productive life of broiler
chickens. The full genetic potential of modern chickens starts at conception and the first 21 d of
embryo development. During this period, variables as temperature or oxygen are important and
any problem related to them could cause a big impact later in life. Hence, the 21 d of
embryogenesis plus the first 7 d of life of the chicken could potentially represent between 50% to
74% of the life of a commercial broiler chicken, depending on the time they are slaughtered (56 or
77 d) (Cherian, 2011). Therefore, earlier administration of probiotics to embryos can have a
profound impact on growth and overall health of the birds.
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In summary, the results of the present study suggest in ovo administration of FloraMax®B11 does not negatively affect HVT vaccine efficacy or hatchability of the chickens, and improves
BW and intestinal integrity during the first 7 d of life while decreasing SE intestinal load in broiler
chickens. Studies to evaluate these effects under commercial conditions are currently underway.
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Table 1.
In ovo evaluation of FloraMax®-B11 on HVT Marek´s vaccine virus stability and incidence of
disease.
HVT only

HVT + FloraMax®-B11

Unchallenged

0/15 (0 %)

0/17 (0 %)

vMDV challenge (583)

3/17 (18 %)

0/17 (0 %)

Unchallenged

1/16 (6 %)

0/17 (0 %)

vMDV challenge (583)

4/15 (27 %)

3/16 (19 %)

Unchallenged

0/17 (0 %)

0/17 (0 %)

vvMDV challenge (Md5)

10/17 (59 %)

9/17 (53 %)

vvMDV challenge (612)

11/17 (65 %)

13/17 (76 %)

Experiment 1 (Trial 1)

Experiment 1 (Trial 2)

Experiment 2

Marek’s disease HVT vaccine was administered in ovo at manufacturer labeled dosage alone or
with FloraMax®-B11 (104 cfu/g). MDV challenge was administered at 5 d of age using 500 pfu
vMDV strain 583 in experiment 1, or 500 pfu vvMDV strains Md5 or 612, respectively. Birds
were monitored until 8 wk of age, then euthanized and measured for MD incidence. P > 0.05
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Table 2.
Effect of in ovo application of FloraMax®-B11 on hatchability.
Treatment

Trial 1

Trial 2

Trial 3

Saline

137/140 (97.8%)

46/48 (95.8%)

144/145 (99.3%)

FloraMax®-B11

121/121 (100%)

47/48 (97.9%)

142/150 (94.6%)

At d 18 eggs were candled and inoculated with either 0.9% saline or FloraMax®-B11 via in ovo
injection into the amnion. On d 21, chicks were pulled from hatchers and hatchability was
determined, P > 0.05.
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Table 3.
Effect of in ovo application of FloraMax®-B11 on microbial composition in the gastrointestinal tract of hatching broiler chickens.
Selective media

Trial 1

Trial 2

Trial 3

and experimental
groups

Whole gut

Fore gut

Hind gut

Fore gut

Saline

8.24 ± 0.27

0.8 ± 0.5

1.6 ± 0.8

4.06 ± 0.52

8.54 ± 0.24

FloraMax®-B11

0.92 ± 0.48 *

0.0 ± 0.0

0.0 ± 0.0

0.05 ± 0.01 *

0.0 ± 0.0 *

Saline

8.70 ± 0.26

4.90 ± 0.5

7.7 ± 0.40

0.00 ± 0.0

0.84 ± 0.60

FloraMax®-B11

6.43 ± 0.94 *

6.20 ± 0.50 *

7.9 ± 0.40

4.33 ± 0.50 *

6.00 ± 0.31 *

Hind gut

Total coliforms/g 1

Total LAB/g 2

54

At d 18 eggs were candled and inoculated with either saline or FloraMax®-B11 via in ovo injection into the amnion. On d 21, chicks
were pulled from the hatchers and for experiment 1, the whole gut (ventriculus to cecum) was aseptically removed. For experiment 2
and 3 the fore gut (ventriculus to Meckel’s diverticulum) and hind gut (Meckel’s diverticulum to cecum) were removed separately.
1 Samples
2

were plated on MacConkey agar to evaluate total coliforms.

Samples were plated on MRS agar to evaluate total lactic acid bacteria.

Data is expressed as Log10 CFU/gram
Data is expressed as mean ± standard error. *Superscripts within columns for each plate indicate significant difference at P < 0.05, n =
12.

Table 4.
Evaluation of in ovo administration of FloraMax®-B11 on hatchability, body weight, and Salmonella enteritidis recovery in broiler
chickens.
Treatment

Hatchability

Day 1

Day 3

Day 7

SE incidence

Log10 SE/g of

BW (g)

BW (g)

BW (g)

Ceca–cecal tonsils

ceca content

24 h PI

24 h PI

Saline

148/150 (98.6 %)

49.13 ± 0.30 a

62.53 ± 0.81 b

132.89 ± 3.06 b

20/20 (100 %)

7.13 ± 1.01 a

FloraMax®-B11

142/150 (94.6 %)

49.72 ± 0.36 a

65.42 ± 0.77 a

144.98 ± 3.02 a

9/20 (45 %) *

5.45 ± 1.25 b
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At d 18 eggs were candled and inoculated with either saline or FloraMax®-B11via in ovo injection into the amnion. On d 21, chicks
were pulled from the hatchers and were challenged with Salmonella Enteritidis (SE) on d of hatch ~104 cfu/chick. Incidence data is
expressed as positive/total chickens (%) at 24 h post inoculation (PI), asterisk indicate significant differences P < 0.001, n = 20/group.
Log10 SE/g of ceca content is expressed as mean ± standard error. abSuperscripts within columns indicate significant differences P <
0.05, n = 12/group.

Table 5.
Evaluation of in ovo administration of FloraMax®-B11 on morphometric analysis of the gastrointestinal tract of hatching broiler
chickens.
Villus surface
Villus height (µm)

Villus width (µm)

Crypt depth (µm)

VH:CD ratio**

Control

223.39 ± 3.55 a

36.01 ± 0.72 a

25.39 ± 0.69 a

49.92 ± 1.15 a

4.74 ± 0.14 b

FloraMax®-B11

234.58 ± 5.19 a

36.14 ± 0.60 a

26.87 ± 0.86 a

39.93 ± 0.88 b

6.09 ± 0.19 a

Control

148.09 ± 4.26 b

27.42 ± 0.86 a

13.10 ± 0.67 b

36.70 ± 1.04 b

4.16 ± 0.12 a

FloraMax®-B11

176.77 ± 5.50 a

29.01 ± 0.78 a

16.47 ± 0.80 a

40.55 ± 1.19 a

4.59 ± 0.21 a

area (mm2)*

Duodenum
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Ileum

a,b

Means with different superscripts within the same column differ significantly (P < 0.05).

* Villus surface area: [2π × (villus width/2) × (villus height)]
** Villus height (VH) to crypt depth (CD) ratio

Chapter IV
Conclusion
This study evaluated the early administration of a probiotic, which could potentially be an
alternative to antibiotics, for use in the poultry industry. In the study discussed in Chapter III, a
commercial probiotic was administered in ovo and evaluated. We assessed if the mixture of the
probiotic and the Marek’s vaccine had an effect on the ability of the vaccine to protect against
Marek’s Disease. The results showed that the administration of the mixture of the vaccine and
the probiotic had no negative effect on the protectiveness of the vaccine when compared with
birds administered the vaccine only. In this study, we also evaluated hatchability and bacterial
recovery from the gastrointestinal tract. The in ovo administration of the probiotic had no effect
on hatchability and significantly reduced coliforms within the gastrointestinal tract at hatch.
Lastly, we evaluated the ability of the probiotic to reduce Salmonella recovery and increase BW
post in ovo inoculation. 24 h post Salmonella challenge we observed a significant reduction in
Salmonella recovery and incidence, along with a significant increase in BW at days 3 and 7.
Which could be a result of the increased villus surface area observed in the ileum of the probiotic
treated group. This study shows a favorable administration technique and probiotic that could
allow for early colonization of beneficial microflora and increased efficiency.
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